Rejected at 5:31 p.m. Oct, 31, 2023 ] by AnKingMed
Author: Ihateanki
Related Note: 1484950422509
Rationale for change

"inverse agonist" ... antagonist... just change it to antagonist

Rejection reason

wrong

Text Text
Extra
Lecture Notes
Empty field
Missed Questions
Empty field
Pathoma
Empty field
Boards and Beyond
Empty field
First Aid
Sketchy
Sketchy 2
Empty field
Sketchy Extra
Picmonic
Empty field
Pixorize
Physeo
Bootcamp
OME
Additional Resources
Empty field
One by one
Empty field
#AK_Other::#AK_Original_Decks::Step_1::Zanki_Pharmacology #AK_Step2_v12::#AMBOSS::DH01sh #AK_Step1_v12::#Pixorize::03_Pharmacology::16_Other_Neuro_Pharm::21_Naloxone #AK_Step1_v12::#AMBOSS::FOag8k #AK_Step1_v12::#UWorld::Step::16052 #AK_Step1_v12::#OME::PreClinical::Neuroscience::Neuroscience_4::Clinical_Cortex::Anesthesia #AK_Step1_v12::#Bootcamp::Pharmacology::04_Side_Effects_and_Toxins::02_Pharmacological_Toxicity_and_Treatment #AK_Step2_v12::#UWorld::Step::12503 #AK_Step1_v12::#FirstAid::13_Psych::03_Pharm::13_Medically_supervised_opioid_withdrawal_and_relapse_prevention::03_Naloxone #AK_Step2_v12::#B&B::13_Psych::03_Substance_Abuse::02_Substance_Abuse_I #AK_Step1_v12::#B&B::01_Anesthesia::01_General::02_Intravenous_Anesthetics::Extra #AK_Step1_v12::#FirstAid::13_Psych::03_Pharm::13_Medically_supervised_opioid_withdrawal_and_relapse_prevention #AK_Step1_v12::#Physeo::09_Pharm::13_Psychiatric::30_Opioid_Withdrawal,_Detoxification_and_Relapse_Prevention #AK_Step1_v12::#UWorld::COMLEX::26550 #AK_Step1_v12::#B&B::19_Psych::03_Substance_Use_Disorders::02_Opioids::Extra #AK_Step2_v12::#UWorld::COMLEX::102301 #AK_Step1_v12::#Physeo::09_Pharm::14_Neuro::21_Opioid_Clinical_Use,_Mechanism_and_Overdose #AK_Step2_v12::#AMBOSS::ZCaZq5 #AK_Step1_v12::#FirstAid::05_Pharm::03_Toxicities_and_Adverse_Effects::03_Specific_toxicity_treatments #AK_Step1_v12::#AMBOSS::vaaAmQ #AK_Step1_v12::^Systems::Neuro::Pharmacology #AK_Step1_v12::#Bootcamp::Psychiatry::08_Substance_Misuse::04_Opioid_Classification #AK_Step2_v12::#UWorld::COMLEX::106686 #AK_Step1_v12::#Physeo::^physeo_image_update #AK_Step1_v12::#Low/HighYield::1-HighYield #AK_Step1_v12::#UWorld::Step::1256 #PANCE::BEHAVIORAL::substance_use #AK_Step2_v12::!Shelf::EM #PANCE::EOR::Family_med #PANCE::EOR::PSYCH #AK_Step1_v12::#SketchyPharm::06_Neuro_&_Psych::01_Anesthetics_&_Analgesics::03_Opiates,_Naloxone,_Naltrexone #AK_Step2_v12::#UWorld::Step::6889 #AK_Step1_v12::#Pixorize::^Missing_image #AK_Step1_v12::#Pixorize::03_Pharmacology::16_Other_Neuro_Pharm::17_Full_Opioid_Agonists #AK_Step1_v12::#UWorld::Step::16502 #AK_Step2_v12::#UWorld::Step::105921 #AK_Step1_v12::#Bootcamp::Psychiatry::08_Substance_Misuse::03_Opioids #AK_Step2_v12::#SketchyPsych::10_Substance_Use/_Medication_Related_Disorders::01_Substance_Use_Overview #AK_Step1_v12::#UWorld::COMLEX::24367 #AK_Step2_v12::#UWorld::#UWSA1 #AK_Step3_v12::#UWorld::5193 #AK_Step1_v12::#Bootcamp::Pharmacology::01_Pharmacodynamics::09_Drug-Receptor_Interactions